Researchers examined the outcomes of 2,022 patients randomly selected to receive tocilizumab and 2,094 patients who received usual care.
Twenty-nine percent of patients receiving tocilizumab died within 28 days compared to 33 percent of patients in the control group.
“This means that for every 25 patients treated with tocilizumab, one additional life would be saved,” the University of Oxford said in a Feb. 11 news release.
Researchers also found the arthritis drug shortened the time to discharge and reduced patients’ need for a ventilator.
The research has not been peer reviewed and follows several other smaller studies that showed mixed results about tocilizumab’s benefit for COVID-19 patients, reports Bloomberg.
More articles on patient safety and outcomes:
Joint Commission starts public reporting of 2 perinatal care measures
ICU deaths have fallen among COVID-19 patients, but progress is stalling
FDA updates guidance on ventilator splitting
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
